Rituximab, a lower-cost treatment, may be as effective at managing RRMS as the approved therapy Ocrevus, a new study from ...

Tolebrutinib, a brain-penetrant BTK inhibitor, may fill a significant unmet need by delaying disability progression in patients with non-relapsing secondary progressive multiple sclerosis.

The following is a summary of “Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab,” published in the April 2025 issue of Journal of ...

One in three women diagnosed with MS will subsequently conceive, therefore consideration of the maternal-infant dyad is ...

The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow ...

In the Phase III MUSETTE study, a higher dose of intravenous Ocrevus (ocrelizumab) did not provide additional benefit in ...

The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.

Neuro-immunologist Stephen Hauser , MD, whose maverick thinking transformed the treatment landscape for patients with ...

No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...

Roche’s phase III MUSETTE trial of Ocrevus high dose in people with relapsing multiple sclerosis fails to meet primary endpoint: Basel Friday, April 4, 2025, 11:00 Hrs [IST] Roc ...

Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing ...

Swiss pharma giant Roche RHHBY faced a setback in its efforts to develop a higher dose of multiple sclerosis drug Ocrevus (ocrelizumab). The company announced that a phase III study, MUSETTE, which ...